Overview
* Cocrystal Pharma ( COCP ) Q3 net loss decreases to $2 mln from $4.9 mln yr/yr
* Company received FDA clearance for CDI-988 Phase 1b norovirus study starting Q1 2026
* Company granted NIH SBIR award to advance influenza A/B replication inhibitor program
Outlook
* Company to start Phase 1b norovirus study in Q1 2026
* Company received NIH SBIR award for influenza A/B program
Result Drivers
* Research and development (R&D) expenses for the third quarter of 2025 were $954,000, compared with $3.2 million for the third quarter of 2024
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$2.05
Income mln
Q3 Basic -$0.19
EPS
Q3 $2.09
Operatin mln
g
Expenses
Q3 -$2.09
Operatin mln
g Income
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the biotechnology & medical research peer group is "buy"
* Wall Street's median 12-month price target for Cocrystal Pharma Inc ( COCP ) is $8.00, about 87.1% above its November 13 closing price of $1.03
Press Release:
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)